Research programme: metabolic disorders therapy - GPC Biotech/Eli LillyAlternative Names: metabolic disorders therapy research programme - GPC Biotech/Eli Lilly
Latest Information Update: 27 Apr 2004
At a glance
- Originator Eli Lilly; GPC Biotech AG
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Metabolic disorders
Most Recent Events
- 27 Apr 2004 Discontinued - Preclinical for Metabolic disorders in USA (unspecified route)
- 27 Apr 2004 Discontinued - Preclinical for Metabolic disorders in Germany (unspecified route)
- 10 Mar 2003 Preclinical trials in Metabolic disorders in Germany (unspecified route)